Metformin Ameliorates Diabetic Cardiomyopathy by Activating the PK2/PKR Pathway

Metformin Ameliorates Diabetic Cardiomyopathy by Activating the PK2/PKR Pathway

Diabetic cardiomyopathy (DCM) is a complication of diabetes that can cause damage to myocardial structure and function. Metformin (Met) is a widely used type 2 diabetes treatment drug that exerts cardioprotective effects through multiple pathways. Prokineticin 2 (PK2) is a small-molecule secreted pr...

Full description

Bibliographic Details
Main Authors: Zhen Yang, Min Wang, Yuchen Zhang, Fei Cai, Botao Jiang, Wenliang Zha, Wei Yu
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Physiology
Subjects:
diabetic cardiomyopathy
prokineticin 2
prokineticin 2 receptors
AKT/GSK3β signaling pathway
apoptosis
Online Access:https://www.frontiersin.org/article/10.3389/fphys.2020.00425/full

Similar Items

Similar Items